Arvinas, Inc.

As of October 3, 2025, Arvinas, Inc. shows a neutral technical trend with mixed signals, having outperformed the S&P 500 recently but significantly underperformed over the longer term.

As of October 3, 2025, Arvinas, Inc. shows a neutral technical trend with mixed indicators, reflecting a recent strong weekly return of 16.20% but a year-to-date decline of 49.87%, suggesting a cautious investment approach.

As of September 2, 2025, Arvinas, Inc. exhibits a mildly bearish trend with a year-to-date return of -59.73%, significantly underperforming the S&P 500's 12.22%.

As of August 6, 2025, Arvinas, Inc. is considered risky and overvalued due to unfavorable metrics, including a Price to Book Value of 0.83, a negative P/E ratio of -10.12, and a year-to-date return of -59.73%, significantly underperforming compared to its peers and the S&P 500.

As of May 1, 2025, Arvinas, Inc. is considered undervalued and has improved from a risky to an attractive valuation grade, with favorable ratios compared to peers, despite its recent stock declines.

As of June 2, 2025, Arvinas, Inc. shows a mildly bearish trend with mixed momentum indicators, including a bullish weekly MACD and bearish monthly MACD, while overall sentiment remains weakly bearish with potential for long-term recovery.

As of March 2022, the management team of Arvinas, Inc. includes Dr. Timothy Shannon (Independent Chairman), Dr. John Houston (President and CEO), and several directors: Ms. Linda Bain, Dr. Wendy Dixon, Mr. Edward Kennedy, Mr. Bradley Margus, and Dr. Briggs Morrison. The team features a blend of executive leadership and independent directors.

Arvinas, Inc. is a biopharmaceutical company focused on developing therapies that degrade disease-causing proteins. As of March 2025, it reported net sales of $189 million and a market cap of approximately $546 million.

As of Jun 18, Arvinas, Inc. has a market capitalization of 545.98 million, with net sales of 324.50 million and a net profit of 2.60 million over the last four quarters.